| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8530982 | International Immunopharmacology | 2018 | 10 Pages |
Abstract
Kurarinone significantly inhibits the clinical progression of EAE through the inhibition of Th1 and Th17 cell differentiation and proliferation. Kurarinone may show promise as an immunomodulatory therapeutic agent in treating MS.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Liang Xie, Wei Gong, Jin Chen, Hong-wu Xie, Man Wang, Xiao-ping Yin, Wei Wu,